Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epizyme has received $4m pre-clinical milestone payment as part of its collaboration with Eisai.
Subscribe to our email newsletter
In March 2011, Epizyme and Eisai signed a global strategic alliance to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme as a treatment for lymphoma and other cancers in genetically-defined patients.
As per the alliance, Epizyme is likely to receive over $200m in research, development and sales milestones and up to double-digit royalties.
Furthermore, Eisai will fund the entire R&D through human proof-of-concept, at which point Epizyme has the right to opt into a profit share and co-commercialization arrangement for the US.
Epizyme EVP and CSO Robert Copeland said EZH2 as an oncogenic target has strong validation in genetically-defined cancers, including subtypes of lymphoma and solid tumors with high unmet therapeutic needs.
"The significant progress we have made in this time affirms Epizyme’s ability to discover and pursue small molecule histone methyltransferase inhibitors as personalized therapeutics for genetically-defined cancer patients," Copeland added.